Genetic Confirmation of Clonal Spread of Candida auris from Southern to Northern Nevada
- PMID: 40558957
- PMCID: PMC12194799
- DOI: 10.3390/jof11060445
Genetic Confirmation of Clonal Spread of Candida auris from Southern to Northern Nevada
Abstract
Candida auris is an emerging fungal pathogen characterized by high levels of antifungal drug resistance and hospital outbreaks in a global distribution. Since introduction to the United States, it has been identified most frequently in New York, Illinois, California, Florida, and Nevada. Its surge poses significant risk as a nosocomial infection with multi-drug resistance, with clades bearing resistance to fluconazole, micafungin, and amphotericin B. Within the state of Nevada, and specifically the greater Las Vegas area in the southern part of the state, there are ongoing outbreaks from clade I and clade III, with 1728 confirmed clinical cases identified as of January 2025. In northern Nevada, three clinical cases have been identified to date, with two occurring at our facility. Both patients had been hospitalized at facilities in Las Vegas, Nevada. The C. auris strains isolated from these two cases have been identified as belonging to clade III and demonstrate resistance to fluconazole. Genome sequencing of the C. auris isolates indicates close genetic identity to strains from the Las Vegas outbreak. These data indicate that the spread of these clonal isolates is due to hospitalization and subsequent patient relocation to northern Nevada, revealing the ongoing importance of screening for geographic spread.
Keywords: Candida auris; Las Vegas; Northern Nevada; case report; geographic spread; outbreak.
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
References
-
- Vaseghi N., Sharifisooraki J., Morovati H., Meis J.F., Ahangarkani F., Khodadadi H., Badali H., Nami S., Safari F. Global prevalence and subgroup analyses of coronavirus disease (COVID-19) associated Candida auris infections (CACa): A systematic review and meta-analysis. Mycoses. 2022;65:683–703. doi: 10.1111/myc.13471. - DOI - PMC - PubMed
-
- Chow N.A., Gade L., Tsay S.V., Forsberg K., Greenko J.A., Southwick K.L., Barrett P.M., Kerins J.L., Lockhart S.R., Chiller T.M., et al. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: A molecular epidemiological survey. Lancet Infect. Dis. 2018;18:1377–1384. doi: 10.1016/S1473-3099(18)30597-8. - DOI - PMC - PubMed
-
- Spruijtenburg B., Badali H., Abastabar M., Mirhendi H., Khodavaisy S., Sharifisooraki J., Taghizadeh Armaki M., de Groot T., Meis J.F. Confirmation of fifth Candida auris clade by whole genome sequencing. Emerg. Microbes Infect. 2022;11:2405–2411. doi: 10.1080/22221751.2022.2125349. - DOI - PMC - PubMed
-
- Suphavilai C., Ko K.K.K., Lim K.M., Tan M.G., Boonsimma P., Chu J.J.K., Goh S.S., Rajandran P., Lee L.C., Tan K.Y., et al. Detection and characterisation of a sixth Candida auris clade in Singapore: A genomic and phenotypic study. Lancet Microbe. 2024;5:100878. doi: 10.1016/S2666-5247(24)00101-0. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
